Pathologic Complete Response to Neoadjuvant Crizotinib in a Lung Adenocarcinoma Patient With a MET Exon 14 Skipping Mutation

Clin Lung Cancer. 2019 Mar;20(2):e137-e141. doi: 10.1016/j.cllc.2018.11.003. Epub 2018 Nov 20.

¹ Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
² Department of Surgery, University of California, San Francisco, San Francisco, CA.
³ Department of Pathology, University of California, San Francisco, San Francisco, CA.
⁴ Department of Radiology, University of California, San Francisco, San Francisco, CA.
⁵ Department of Medicine, University of California, San Francisco, San Francisco, CA; Hellen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA. Electronic address: Collin.blakely@ucsf.edu.

No abstract available

Keywords: Non-small cell lung cancer; Perioperative; Stage III; Targeted therapy; Tyrosine kinase inhibitor.

Publication types